Background: CGM devices have been shown to improve glycemic control in patients with T1D. Despite existing clinical evidence and improved performance of CGM devices, only a small proportion of patients are using CGM.

Methods: The T1D Exchange QI Collaborative (T1DX-QI) is a large cohort with twelve national clinics engaged in data sharing and quality improvement to improve outcomes. This analysis used the T1DX-QI database to examine patient attributes associated with CGM device use. Patients with one or more completed clinic encounters during the years 2017-2019 were included (N=16,414) and classified as CGM users if they indicated information on a device start date, model or company within the past one year of their most recent diabetes clinic visit. We examined the frequency of CGM device use and distribution of socio-demographic factors, as well as clinical outcomes, among CGM users versus non-users.

Results: In this cohort, 27.4% of T1D patients were CGM users, with patients aged ≤26 years being more likely to use CGM. Among CGM users, 75% used a real-time device, a 3% intermittent scanning device, and 22% device type was unknown. CGM use was more likely among Non-Hispanic Whites (75%) and patients on private health insurance (72%) relative to Non-Hispanic Black patients (3%) and those on public health insurance (27%) [p<0.001]. HbA1c levels among CGM users were lower relative to non-users after adjusting for age, race/ethnicity and insurance status (8.3%± 1.7% vs. 8.8%±1.9%) [p<0.001].

Conclusion: This study highlights patient factors and clinical outcomes among CGM users in the T1DX-QI Collaborative, one of the largest sources of real world data for T1D available to-date. The findings shed light on socio-demographic variability in CGM uptake with implications for targeted interventions to promote device use in this subset of the T1D population.


N. Noor: None. N. Rioles: None. S. Majidi: Advisory Panel; Self; Companion Medical. S. Corathers: None. R. McDonough: None. S. Polsky: None. M. Greenfield: None. K. Obrynba: None. O. Ebekozien: None. D. DeSalvo: Consultant; Self; Dexcom, Inc., Insulet Corporation.


The Leona M. and Harry B. Helmsley Charitable Trust

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at